A recent study demonstrated that inhibition of NF-κB with bortezomib, proteasome inhibitor, enhanced the anti-tumor effects of docetaxel [21], which could lead to improved treatment outcomes by reducing chemoresistance. The gene discussed is NFKB1; the disease is neoplasm.